argentinian registry of patients with rheumatic diseases and covid-19 infection

Conditions: Rheumatic Diseases

Summary: sar-covid is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and sars-cov-2 infection (asymptomatic or covid-19). hypothesis: patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder covid-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments.

sar-covid is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and sars-cov-2 infection (asymptomatic or covid-19). hypotesis: patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder covid-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments. target population: patients \> 18 years of age with any rheumatic disease. eligibility criteria inclusion criteria * age \> 18 years. * patients with diagnosis of rheumatic diseases (treated or not with immunomodulatory and/or immunosuppressive drugs). * patients with diagnosis of sars-cov-2 infection (past or present) with positive test for the virus sars-cov-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms. exclusion criteria • patients who do not wish to participate or are unable to give informed consent. recruitment: all rheumatologists, members of the argentine society of rheumatology will be invited to participate in the registry. it is expected that 3,000 patients with covid-19 and some rheumatic disease, who are cared for by rheumatologists in any of the 23 provinces of argentina, will be enrolled in the sar-covid registry during the period from july 1 to december 31, 2020. twelve-month extension of the recruitment period will be applied if the expected number of patients is not achieved by the end of the inclusion date. two cohorts will be included: the first will enroll 1,500 patients treated with immunomodulatory and/or immunosuppressive drugs, and the second will enroll 1,500 patients without immunomodulatory and/or immunosuppressive drugs. data collection: all variables will be collected by self-report, clinical and laboratory examination and/or medical records review, performed by the rheumatologist during patient hospitalization due to covid-19, or at the patient control visit performed after sars-cov-2 infection. the data will be entered into the arthros ecrf (online application designed ad hoc), which in turn will facilitate generating queries and perform the statistical analysis. periodic reports: patients will be followed up for 12 months, in order to evaluate their evolution and identify the effect of the sars-cov-2 infection on their rheumatological disease. for this reason, in this registry the data will be collected in two phases: * phase i: corresponds to the baseline visit (t0). sociodemographic data, diagnosis, symptoms, treatment, hospitalization, complications, characteristics of the rheumatic disease and its treatment before and during the infectious process will be recorded. * phase ii: this second visit (t1) will be carried out 12 months after patients registration. its objective is to identify long-term complications after sars-cov-2 infection and to assess the impact of infection on rheumatic disease.

Eligibility criteria:
inclusion criteria: * age equal or older than 18 years. * patients with diagnosis of rheumatic diseases (treated or not with immunomodulatory and/or immunosuppressive drugs). * patients with diagnosis of sars-cov-2 infection (past or present) with positive test for the virus sars-cov-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms. exclusion criteria: * patients who do not wish to participate or are unable to give informed consent.

Keywords: covid-19